These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 9338750)
1. p53 and HER-2 alterations in renal cell carcinoma. Zhang XH; Takenaka I; Sato C; Sakamoto H Urology; 1997 Oct; 50(4):636-42. PubMed ID: 9338750 [TBL] [Abstract][Full Text] [Related]
2. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Hofmockel G; Wittmann A; Dammrich J; Bassukas ID Anticancer Res; 1996; 16(6B):3807-11. PubMed ID: 9042262 [TBL] [Abstract][Full Text] [Related]
3. Mutant p53 expression in kidney tubules adjacent to renal cell carcinoma: evidence of a precursor lesion. Lai R; el Dabbagh L; Mourad WA Mod Pathol; 1996 Jun; 9(6):690-5. PubMed ID: 8782209 [TBL] [Abstract][Full Text] [Related]
4. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139 [TBL] [Abstract][Full Text] [Related]
5. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Iacopetta B; Grieu F; Powell B; Soong R; McCaul K; Seshadri R Clin Cancer Res; 1998 Jul; 4(7):1597-602. PubMed ID: 9676832 [TBL] [Abstract][Full Text] [Related]
6. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048 [TBL] [Abstract][Full Text] [Related]
7. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872 [TBL] [Abstract][Full Text] [Related]
8. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467 [TBL] [Abstract][Full Text] [Related]
9. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413 [TBL] [Abstract][Full Text] [Related]
10. Value of p53 expression, cellular proliferation, and DNA content as prognostic indicators in renal cell carcinoma. Papadopoulos I; Rudolph P; Weichert-Jacobsen K Eur Urol; 1997; 32(1):110-7. PubMed ID: 9266242 [TBL] [Abstract][Full Text] [Related]
11. [Expression of S100 protein in renal cell carcinoma and its relation with P53]. Yang JF; Zhang XY; Qi F Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Jun; 29(3):301-4. PubMed ID: 16136965 [TBL] [Abstract][Full Text] [Related]
12. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. Contractor H; Zariwala M; Bugert P; Zeisler J; Kovacs G J Pathol; 1997 Feb; 181(2):136-9. PubMed ID: 9120715 [TBL] [Abstract][Full Text] [Related]
13. p53 expression in human renal cell carcinoma: an immunohistochemical study and a literature outline of the cytogenetic characterization. Tomasino RM; Morello V; Tralongo V; Nagar C; Nuara R; Daniele E; Curti M; Orestano F Pathologica; 1994 Jun; 86(3):227-33. PubMed ID: 7808790 [TBL] [Abstract][Full Text] [Related]
14. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development. Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001 [TBL] [Abstract][Full Text] [Related]
15. p53 mutation is infrequent in clear cell carcinoma of the ovary. Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858 [TBL] [Abstract][Full Text] [Related]
16. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029 [TBL] [Abstract][Full Text] [Related]
17. Mutations of p53 gene in gastric carcinoma in Taiwan. Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797 [TBL] [Abstract][Full Text] [Related]
18. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis. Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773 [TBL] [Abstract][Full Text] [Related]
19. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660 [TBL] [Abstract][Full Text] [Related]
20. Expression of p53 isoforms in renal cell carcinoma. Song W; Huo SW; Lü JJ; Liu Z; Fang XL; Jin XB; Yuan MZ Chin Med J (Engl); 2009 Apr; 122(8):921-6. PubMed ID: 19493415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]